Topics

Latest "Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL" News Stories

09:10 EST 10th December 2019 | BioPortfolio

Here are the most relevant search results for "Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL" found in our extensive news archives from over 250 global news sources.

More Information about Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL for you to read. Along with our medical data and news we also list Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL Clinical Trials, which are updated daily. BioPortfolio also has a large database of Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL Companies for you to search.

Showing "Intranasal Retinoic Acid Treatment Patients With OlfactoryLOSS RANDOMIZED" News Articles 1–25 of 36,000+

Tuesday 10th December 2019

FocalPoint Holdings Partners with GreenSky Patient Solutions® to Enable 8,000 Ophthalmology Providers to Provide Patient Financing

FocalPoint Holdings, LLC today announced a partnership with GreenSky Patient Solutions, LLC, a subsidiary of GreenSky, Inc. (“GreenSky”) (NASDAQ: GSKY), a leading financial technology company Powering Commerce at the Point of Sale®. This partnership enables FocalPoint Holdings’ network of 8,000 ophthalmology and optometry providers to offer flexible financing solutions, including revolving...


Leafly Announces Partnership With the American Medical Marijuana Physicians Association (AMMPA) to Help Doctors Better Serve Their Patients

Leafly and AMMPA will work together on event programming and online education for physicians Leafly, the world’s leading cannabis resource, today announced a strategic partnership with the

PharmaCyte Biotech to Hold Quarterly Shareholder Update

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its quarterly shareholder update will be held on December 20, 2019 at 4 P.M. EST. The update will include the latest information available on preparing to submit an Investigati...


Liver Cirrhosis Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08042019] Prices from USD $1583

Summary Liver Cirrhosis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Liver Cirrhosis RD activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.Extensive Coverage of Pipeline CandidatesThe Liver Cirrhosis report covers all the preclinical ...

Sanofi's C1s inhibitor sutimlimab increases haemoglobin levels in patients with primary cold agglutinin disease https://www.firstwordpharma.com/node/1686793  $SNY #ASH19

Sanofi's C1s inhibitor sutimlimab increases haemoglobin levels in patients with primary cold agglutinin disease https://www.firstwordpharma.com/node/1686793  $SNY #ASH19

Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluro

Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for lebrikizumab, its novel, investigational treatment being evalua...

2019 Metrorrhagia Abnormal Uterine Bleeding Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583

The global clinical trial report 2019 Metrorrhagia Abnormal Uterine Bleeding Clinical Trials Study provides complete list of trials completed, ongoing and planned for Metrorrhagia Abnormal Uterine Bleeding. It presents indepth analysis of Metrorrhagia Abnormal Uterine Bleeding clinical trials across markets and companies. The research work is for providing complete understanding into trends in Me...

Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies

Partnership will leverage Bit Bio’s unique ability to generate authentic human cells at scale Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for

AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

AgeX Therapeutics, Inc. (NYSE American: AGE) and Lineage Cell Therapeutics, Inc. (NYSE American and TASE LCTX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Pate

Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has

Greenville Men’s Clinic Opens State-of-the-Art Location in Greenville, South Carolina

Greenville Men's Clinic is proud to announce the grand opening of our newest men's health clinic in Greenville, South Carolina. They offer fast, effective treatments for Erectile Dysfunction, Peyronies Disease, Low Testosterone, and Premature Ejaculation. GREENVILLE, S.C. (PRWEB) December 10, 2019 A new state-of-the-art men’s clinic is opening its doors in Greenville, South Carolina. Gr...

The Black Box of Drug Pricing Has Been Opened; PBM MC-Rx Urges Accountability

Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. More states will follow. These laws represent an important first step in shining a light on why drug prices are rapidly rising. MC-Rx, a PBM advocating for change, argues the need not just for transparency, but accountability in the often secretive flow of funds f...

LEO Pharma Joins Certara’s PBPK Simcyp Simulator Consortium

37 leading biopharmaceutical companies now participate in this unique research and development group focused on advancing model-informed drug development Certara®, the global model-informed drug development and decision support leader, today announced that LEO Pharma has licensed its proprietary Simcyp® Population-based Simulator and joined its Consortium. The Simcyp Simulator Consortium, whic...

Imperative Care Announces $85 Million Series C Financing for Innovative Stroke Treatments

Funds to Fuel Commercialization of Breakthrough Technologies in Stroke Care to Enable Improved Patient Outcomes Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in neurovascular devices treating ischemic and hemorrhagic stro...

Aro Biotherapeutics Names Seasoned Biopharma Industry Veteran Scott Greenberg as Vice President, Business Development and Alliance Management

Aro Biotherapeutics Company announces that Scott Greenberg has joined the company as Vice President, Business Development and Alliance Management. He brings to the company a wealth of experience across a number of functional disciplines in both oncology and immunology garnered at Roivant Sciences and Celgene Corporation. “Scott’s diverse experience at both large and small biopharmaceutical ...

François Nader, M.D., Joins Moderna’s Board of Directors

Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna’s progress towards late-stage development and commercialization Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that François Nader, M.D., M.B.A. has joine...

PolarityTE Builds Patent Portfolio with New International Patent Grants

Significant milestone reached in 2019 with additional patent applications approved in three countries PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that the company has recently been granted a patent in New Zealand and has received approvals for patent applications in the United Kingdom and Au...

Progenity and Geisinger Publish First Study of Primary, Case-Based Data on Economic Burden of Preeclampsia

Progenity, a privately held biotechnology company, and Geisinger, one of the nation’s most innovative health services organizations, announced pu

First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-threatening Ischemia

Clinical Study to Evaluate Device’s Ability to Prevent Amputation and Promote Wound Healing in Patients with No Other Options LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the first patient has been treated in its PROMISE II U.S. piv...

Digital Health Company Earns FDA Clearance for Second Patient Risk Index

Etiometry Inc., a leading digital health company, today announced the FDA clearance of their second algorithm, the Inadequate Ventilation of Carbon Dioxide (IVCO2) Index™. The IVCO2 Index, along with the already cleared Inadequate Delivery of Oxygen (IDO2) Index™, will be displayed on Etiometry’s critical care software platform which is utilized in top hospitals throughout the world. “T...

Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001

Maintenance treatment with CC-486 resulted in a significant improvement in overall survival compared with placebo for front-line AML patients CC-486 had a manageable safety profile Data presented at the 2019 American Society of Hematology (ASH) Annual Meeting Bristol-Myers Squibb Company (NYSE: BMY) today announced clinical results from the QUAZAR AML-001 study, evaluating investigati

Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718 Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announc...

ZYUS Life Sciences Receives Processing Licence from Health Canada to Produce Medical Cannabis Products

Extraction, formulation and production of medical cannabinoid-based therapeutics expected to begin during first quarter 2020 ZYUS Life Sciences Inc. (“ZYUS” or the “Company”) is pleased to announce that effective December 6, 2019, it received a “3 year” Standard Processing Licence from Health Canada for its Saskatoon-based Phase I processing facility (the “Processing Licence”). T...

2019 Sicca Syndrome Sjogren Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583

The global clinical trial report 2019 Sicca Syndrome Sjogren Clinical Trials Study provides complete list of trials completed, ongoing and planned for Sicca Syndrome Sjogren. It presents indepth analysis of Sicca Syndrome Sjogren clinical trials across markets and companies. The research work is for providing complete understanding into trends in Sicca Syndrome Sjogren. The report covers a key sn...


Quick Search

News Quicklinks